Cargando…

Growth Arrest of BCR-ABL Positive Cells with a Sequence-Specific Polyamide-Chlorambucil Conjugate

Chronic myeloid leukemia (CML) is characterized by the presence of a constitutively active Abl kinase, which is the product of a chimeric BCR-ABL gene, caused by the genetic translocation known as the Philadelphia chromosome. Imatinib, a selective inhibitor of the Bcr-Abl tyrosine kinase, has signif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chou, C. James, O'Hare, Thomas, Lefebvre, Sophie, Alvarez, David, Tyner, Jeffrey W., Eide, Christopher A., Druker, Brian J., Gottesfeld, Joel M.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2571993/ https://www.ncbi.nlm.nih.gov/pubmed/18974832 http://dx.doi.org/10.1371/journal.pone.0003593

Ejemplares similares

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia
por: Zabriskie, M S, et al.
Publicado: (2016)

A BCR-ABL Mutant Lacking Direct Binding Sites for the GRB2, CBL and CRKL Adapter Proteins Fails to Induce Leukemia in Mice
por: Johnson, Kara J., et al.
Publicado: (2009)

Unanticipated differences between α- and γ-diaminobutyric acid-linked hairpin polyamide-alkylator conjugates
por: Tsai, Sherry M., et al.
Publicado: (2007)

Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1
por: Zabriskie, Matthew S., et al.
Publicado: (2015)

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
por: Pietarinen, Paavo O., et al.
Publicado: (2017)

Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide–chlorambucil conjugate
por: Funasaki, Shintaro, et al.
Publicado: (2022)

Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib
por: Qiang, Wang, et al.
Publicado: (2017)

Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
por: Smith, Brittany M., et al.
Publicado: (2021)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands
por: Shibata, Norihito, et al.
Publicado: (2017)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Kinase Inhibitor Therapy in CML: It's What's Inside That Counts
por: Eide, Christopher A., et al.
Publicado: (2013)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Redox-Responsive Heparin–Chlorambucil Conjugate Polymeric Prodrug for Improved Anti-Tumor Activity
por: Andrgie, Abegaz Tizazu, et al.
Publicado: (2019)

A Coiled-Coil Mimetic Intercepts BCR-ABL1 Dimerization in Native and Kinase-Mutant Chronic Myeloid Leukemia
por: Woessner, David W., et al.
Publicado: (2015)

A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
por: Wagle, M, et al.
Publicado: (2016)

Chlorambucil-monoglutathionyl conjugate is sequestered by human alpha class glutathione S-transferases.
por: Meyer, D. J., et al.
Publicado: (1992)

Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione.
por: Barnouin, K., et al.
Publicado: (1998)

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia
por: Bandyopadhyay, Shovik, et al.
Publicado: (2017)

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukemia
por: Rafiei, Anahita, et al.
Publicado: (2015)

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
por: Hoelbl, Andrea, et al.
Publicado: (2010)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Tumor Targeting by Conjugation of Chlorambucil with Zwitterionic Near-Infrared Fluorophore for Cancer Phototherapy
por: Jo, Gayoung, et al.
Publicado: (2022)

Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
por: Bucur, Octavian, et al.
Publicado: (2013)

EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway
por: Huang, Rui, et al.
Publicado: (2018)

Retraction Note: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
por: Wu, L. X., et al.
Publicado: (2020)

FISH mapping of Philadelphia negative BCR/ABL1 positive CML
por: Virgili, Anna, et al.
Publicado: (2008)

The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by Imatinib
por: Haaß, Wiltrud, et al.
Publicado: (2012)

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
por: Fei, Fei, et al.
Publicado: (2010)

IMPENDING CARDIAC TAMPONADE AS THE INITIAL MANIFESTATION OF BCR-ABL-POSITIVE CML
por: Gaballa, Salem, et al.
Publicado: (2020)

Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended
por: Huet, Sarah, et al.
Publicado: (2014)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t6a1l6q7l5ncg3d6kgmpm6vvmm